Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
Efficacy findings were consistent with results of the GO29365 study (NCT02257567); treatment with Pola+BR led to clinically meaningful improvements in response rates in Chinese patients with transplant-ineligible R/R DLBCL with no new safety signals.
Authors
- Rong Deng (ORCID: https://orcid.org/0000-0003-2005-7517)
- Lisa Musick
- Yuqin Song (ORCID: https://orcid.org/0000-0001-5451-6481)
- Jamie Hirata
- Xin Wang (ORCID: https://orcid.org/0000-0001-8051-1481)
- Li Wang (ORCID: https://orcid.org/0000-0002-9270-4544)
- Wenxin Liu (ORCID: https://orcid.org/0000-0002-5733-1244)
- Liling Zhang (ORCID: https://orcid.org/0000-0002-0198-2603)
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0001-8116-5293)
- Jun Zhu (ORCID: https://orcid.org/0000-0002-2729-4884)
- Pengcheng He
- Qingqing Cai
- Yongping Song
Institutions
- Union Hospital (HK)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Roche (China) (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Jiangsu Province Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Huazhong University of Science and Technology (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2024-12-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_269_24
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42